Provided by Tiger Trade Technology Pte. Ltd.

Ensysce Biosciences Inc.

0.3950
-0.0048-1.20%
Post-market: 0.39520.0002+0.05%19:30 EDT
Volume:173.96K
Turnover:69.81K
Market Cap:7.69M
PE:-0.14
High:0.4266
Open:0.4100
Low:0.3930
Close:0.3998
52wk High:2.75
52wk Low:0.2300
Shares:19.46M
Float Shares:18.38M
Volume Ratio:0.81
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7523
EPS(LYR):-3.9790
ROE:-1295.09%
ROA:-185.51%
PB:-9.83
PE(LYR):-0.10

Loading ...

Ensysce Biosciences Amends Series C Preferred Terms, Removes Holder Cash Redemption Right

Reuters
·
Sep 29

Ensysce Submits UK MHRA Phase 2a Trial Protocol for CRPS Drug Candidate CY200

Reuters
·
Sep 24

Ensysce Biosciences to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 02

Ensysce completes enrollment for final phase of PF614-MPAR-102 study

TIPRANKS
·
Aug 31

Ensysce Completes Enrollment in Final Stage of PF614-MPAR-102 Overdose-Protection Opioid Study

Reuters
·
Aug 31

Ensysce Biosciences Wins NASDAQ Stockholders’ Equity Compliance, Still Faces Delisting Risk if Next Filing Falls Short

Reuters
·
Aug 26

Ensysce Biosciences Raises over $21 Million in Series C Preferred Stock Private Placement

Reuters
·
Aug 25

Ensysce Biosciences Director Bob G. Gower Acquires Common Shares Worth $443,025.17

Reuters
·
Aug 18

Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise

Reuters
·
Aug 14

Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate

Benzinga Earnings
·
Aug 14

Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 14

Ensysce Biosciences Q2 EPS USD -0.2

THOMSON REUTERS
·
Aug 14

Ensysce Biosciences Files Form 3 for President, Director James William Morrison

Reuters
·
Aug 11

Ensysce Biosciences Inc Expected to Post a Loss of 50 Cents a Share - Earnings Preview

Reuters
·
Aug 07

NASDAQ Trade Halt Volatility Trading Pause at 09:42 Am

Reuters
·
Aug 06

Ensysce Biosciences Posts Investor Presentation Spotlighting Trypsin-Controlled Opioid Platforms, Pain Pipeline

Reuters
·
Aug 06

Ensysce Biosciences Completes Cy Biopharma Acquisition

Reuters
·
Aug 06

Top Premarket Gainers

MT Newswires Live
·
Aug 04

Ensysce Biosciences COO Jeffrey Millard Resigns

Reuters
·
Jul 16

Ensysce Biosciences: Awarded $5.3 Mln Installment in Nida Funding Completing Multi-year $15 Mln Federal Grant

THOMSON REUTERS
·
Jul 14